Clinical Trials Directory

Trials / Completed

CompletedNCT02829476

Ghrelin Resistance in Adolescents With Idiopathic Scoliosis

Ghrelin Cellular Resistance Study in Adolescents With Idiopathic Scoliosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
45 (actual)
Sponsor
University Hospital, Toulouse · Academic / Other
Sex
All
Age
12 Years – 15 Years
Healthy volunteers
Not accepted

Summary

Adolescent idiopathic Scoliosis (AIS) is the most common spine pathology. It is opposed to secondary scoliosis due to chronic diseases. Many hypotheses have been made to elucidate the origin of this illness. Recently, the melatonin pathway has been investigated as pinealectomy of the chicken creates a scoliosis that resembles AIS and melatonin supplementation reverses the process. In addition administration of melatonin to AIS patients improved the pathology. However this hypothesis has shown controversial results. Recent studies have demonstrated melatonin cellular resistance in osteoblastic cells from AIS patients. Melatonin acts through G protein coupled receptor (GPCR), mainly using the Gi pathway. In AIS osteoblasts, this pathway is blocked leading to a decrease in the inactivation of the adenylyl cyclase and therefore maintenance of high level of cyclic adenosine monophosphate (cAMP) concentrations in the cells. As modulation of cAMP is important for osteogenesis such resistance may be critical for the initiation or the development of AIS. Gi signalization is used by several other GPCR, thus, this hormonal resistance could logically be found in other hormonal or mediator pathways. A precedent study previously focused on ghrelin in AIS, and demonstrated that AIS patients possess elevated plasmatic values of ghrelin. This study also observed decreased response to ghrelin in AIS cultures osteoblasts.

Conditions

Interventions

TypeNameDescription
BIOLOGICALOsteoblast sampleculture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis

Timeline

Start date
2010-03-01
Primary completion
2012-07-01
Completion
2012-07-01
First posted
2016-07-12
Last updated
2017-05-12

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02829476. Inclusion in this directory is not an endorsement.